{
    "id": "24c3ea00-3c09-449b-afee-29b64af39926",
    "indications": {
        "text": "eplerenone aldosterone antagonist indicated : \u2022 improving survival stable patients symptomatic heart failure reduced ejection fraction ( hfref ) acute myocardial infarction . ( 1.1 ) \u2022 treatment hypertension , lower blood pressure . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions . ( 1.2 )",
        "doid_entities": [
            {
                "text": "acute myocardial infarction (DOID:9408)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9408"
            },
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute myocardial infarction",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_95409"
            }
        ]
    },
    "contraindications": {
        "text": "hfref post-myocardial infarction : initiate treatment 25 mg daily . titrate maximum 50 mg daily within 4 weeks , tolerated . dose adjustments may required based potassium levels . ( 2.1 ) hypertension : 50 mg daily , alone combined antihypertensive agents . inadequate response , increase 50 mg twice daily . higher dosages recommended . ( 2.2 ) patients : measure serum potassium starting eplerenone periodically thereafter . ( 2.3 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "eplerenone tablets yellow , diamond biconvex , film-coated . debossed \u201c vle \u201d one side . supplied follows : dose debossside 2 ndc 59762-xxxx-x bottle/30 bottle/90 25 mg nsr25 1107-2 1107-3 50 mg nsr50 1108-1 1108-2 store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u201330\u00b0c ( 59\u201386\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "patients eplerenone contraindicated patients : \u2022serum potassium > 5.5 meq/l initiation , \u2022creatinine clearance \u2264 30 ml/min , \u2022concomitant strong cyp3a inhibitors ( e.g . , ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) [ ( 7.1 ) , pharmacology ( 12.3 ) ] . patients treated hypertension eplerenone contraindicated treatment hypertension patients : \u2022type 2 diabetes microalbuminuria , \u2022serum creatinine > 2.0 mg/dl males > 1.8 mg/dl females , \u2022creatinine clearance < 50 ml/min , \u2022concomitant potassium supplements potassium-sparing diuretics ( e.g . , amiloride , spironolactone , triamterene ) [ ( 5.1 ) , ( 6.2 ) , ( 7 ) , pharmacology ( 12.3 ) ] .",
    "ingredients": [
        {
            "name": "EPLERENONE",
            "code": "6995V82D0B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31547"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "organization": "Mylan Pharmaceuticals Inc.",
    "name": "Eplerenone",
    "effectiveTime": "20240305",
    "indications_original": "Eplerenone is an aldosterone antagonist indicated for: \u2022 Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) \u2022 The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 )",
    "contraindications_original": "HFrEF Post-MI : Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. ( 2.1 ) Hypertension : 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice daily. Higher dosages are not recommended. ( 2.2 ) For all patients : Measure serum potassium before starting eplerenone and periodically thereafter. ( 2.3 )",
    "warningsAndPrecautions_original": "Eplerenone tablets are yellow, diamond biconvex, and film-coated. They are debossed with \u201cVLE\u201d on one side. They are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Dose\n                           \n                           \n                              DebossSide 2\n                           \n                           \n                              NDC 59762-xxxx-x\n                           \n                        \n                        \n                           \n                              Bottle/30\n                           \n                           \n                              Bottle/90\n                           \n                        \n                        \n                           \n                              25 mg\n                           \n                           \n                              NSR25\n                           \n                           \n                              1107-2\n                           \n                           \n                              1107-3\n                           \n                        \n                        \n                           \n                              50 mg\n                           \n                           \n                              NSR50\n                           \n                           \n                              1108-1\n                           \n                           \n                              1108-2\n                           \n                        \n                     \n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u201330\u00b0C (59\u201386\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "For All Patients\n                     \n                  \n                  Eplerenone is contraindicated in all patients with:\n                  \n                     \n                        \u2022serum potassium >5.5 mEq/L at initiation,\n                     \n                        \u2022creatinine clearance \u2264 30 mL/min, or\n                     \n                        \u2022concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].\n                  \n                  \n                     \n                        For Patients Treated for Hypertension\n                     \n                  \n                  Eplerenone is contraindicated for the treatment of hypertension in patients with:\n                  \n                     \n                        \u2022type 2 diabetes with microalbuminuria,\n                     \n                        \u2022serum creatinine >2.0 mg/dL in males or >1.8 mg/dL in females,\n                     \n                        \u2022creatinine clearance <50 mL/min, or\n                     \n                        \u2022concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1), Adverse Reactions (6.2), Drug Interactions (7), and Clinical Pharmacology (12.3)].",
    "drug": [
        {
            "name": "Eplerenone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31547"
        }
    ]
}